A prospective study of unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia.
Unfractionated heparin therapy was initiated at a standard dosage of 300 IU/kg subcutaneously q 6 hours to 18 dogs with immune-mediated hemolytic anemia. Heparin's prolongation of activated partial thromboplastin time and change in factor Xa inhibition (anti-Xa activity) were serially monitored during the first 40 hours of therapy. During the initial 40 hours, only eight of 18 dogs had attained anti-Xa activities of > or =0.35 U/mL. No dogs had clinical signs of hemorrhage. Fifteen dogs survived to discharge; 11 dogs were alive at 1 year, and thrombosis was identified in three of six nonsurvivors that were necropsied.
Breuhl
Elizabeth L
EL
Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Lynn Hall, Purdue University, West Lafayette, Indiana 47907, USA.
Moore
George
G
Brooks
Marjory B
MB
Scott-Moncrieff
J Catharine
JC
D000744:Anemia, Hemolytic, Autoimmune / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D004285:Dogs; D015951:Factor Xa / Q000032:analysis; D065427:Factor Xa Inhibitors; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D007087:Illinois / Q000453:epidemiology; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D016019:Survival Analysis; D013923:Thromboembolism / Q000150:complications / Q000401:mortality / Q000662:veterinary*; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006493:Heparin; D015951:Factor Xa